Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Novel Therapeutics for Ovarian Cancer

Abstract NTOC-100: OVARIAN TUMOR-ASSOCIATED GRP78 INDUCES IMMUNOSUPPRESSION AND WITHAFERIN A (ASHWAGANDHA) ENHANCES ANTI-TUMOR IMMUNITY

Sa'Rah McNeal, Pincas Bitterman, Janice M Bahr, William P Hanafin, Sameer Sharma, Sanjib Basu and Animesh Barua
Sa'Rah McNeal
1Rush University Medical Center, Chicago, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pincas Bitterman
1Rush University Medical Center, Chicago, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janice M Bahr
2University of Illinois at Urbana-Champaign, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William P Hanafin
2University of Illinois at Urbana-Champaign, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sameer Sharma
1Rush University Medical Center, Chicago, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjib Basu
1Rush University Medical Center, Chicago, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Animesh Barua
1Rush University Medical Center, Chicago, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1557-3265.OVCASYMP16-NTOC-100 Published June 2017
  • Article
  • Info & Metrics
Loading
Abstracts: 11th Biennial Ovarian Cancer Research Symposium; September 12-13, 2016; Seattle, WA

Abstract

BACKGROUND: Tumor-induced immunosuppression is a hallmark of tumor progression. Local immune function in the tumor vicinity plays a pivotal role in prevention of OVCA progression. Natural killer (NK) cells and cytotoxic T cells are important for anti-tumor immune function. NK cells recognize tumor cells through NKG2D receptor which binds with ligands expressed on the surface of tumor cells. Tumor cells escape NK cell by shedding NKG2D ligands from their surface. Tumors also avoid recognition by cytotoxic T cells. The mechanism of tumor-induced immunosuppression is not well understood. Glucose-regulated protein 78 (GRP78) has been suggested to increase in several malignancies. GRP78 is a marker of cellular stress and may be involved in tumor-induced immunosuppression. Understanding the mechanism of NK and T cell immunosuppression by OVCA is essential to develop effective immunotherapy.

OBJECTIVE: The goal of this study was to examine whether OVCA-induced GRP78 was associated with suppression of anti-tumor NK and T cell immunity, and whether Ashwagandha (ASH, Withania somnifera, a source of Withaferin-A and an anti-stress herbal supplement) can prevent OVCA-induced immunosuppression.

MATERIALS AND METHODS: Experiment-1: Normal postmenopausal ovaries (n=10), OVCA at early stage (papillary serous, endometrioid, mucinous and clear cell, n=5 each), and papillary serous at late stage (n=10) clinical samples were used. Tissues were examined for GRP78, NKG2D-expressing cells, CD8 T cells, ADAM10 (a cell surface expressing protease), and miRNA-180a (regulator of GRP78 expression). Experiment-2: Laying hens (4-year old) with OVCA at early stage were selected by transvaginal ultrasound imaging and divided into 2 groups, each with 20 normal and 20 OVCA. The control group received regular layer ration and the other group received diet supplemented with 2% ASH root powder for 120 days. Serum samples were collected before the start and at the time of euthanasia. Animals were sacrificed; gross morphology and tumor stages were recorded. Normal and cancerous ovaries were processed to examine the expression of OVCA markers mentioned above.

RESULTS: Stromal population of NKG2D-expressing cells and CD8 T cells were significantly higher in OVCA compared to normal ovaries (P<0.01). Significant differences were not observed in the frequency of intra-tumoral immune cells between OVCA at early and late stages. The intensity of GRP78 and ADAM10 expression by malignant cells increased significantly in association with OVCA progression (P<0.001). Increased GRP78 expression was associated with decreased expression of miRNA-180a. Ash supplementation inhibited tumor progression in 15 of 20 OVCA hens. Compared with untreated, GRP78 expression decreased significantly (P<0.001) in ASH-treated hens. The frequency of stromal and intratumoral NK and CD8 T cells increased significantly (P<0.05) in ASH-treated hens compared to control hens. ASH-treatment also increased miRNA-180a expression in hens.

CONCLUSION: OVCA progression was associated with increased GRP78 and ADAM10 expression which might be involved in decreased intra-tumoral immune cell infiltration. ASH supplementation enhanced anti-OVCA immune function by reducing tumor-associated cellular stress including GRP78 expression. Thus, ASH represents a potential GRP78-targeted anti-OVCA immunotherapy. Support: NIH/NCI R21CA187309.

Citation Format: Sa'Rah McNeal, Pincas Bitterman, Janice M Bahr, William P Hanafin, Sameer Sharma, Sanjib Basu, Animesh Barua. OVARIAN TUMOR-ASSOCIATED GRP78 INDUCES IMMUNOSUPPRESSION AND WITHAFERIN A (ASHWAGANDHA) ENHANCES ANTI-TUMOR IMMUNITY [abstract]. In: Proceedings of the 11th Biennial Ovarian Cancer Research Symposium; Sep 12-13, 2016; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(11 Suppl):Abstract nr NTOC-100.

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Clinical Cancer Research: 23 (11 Supplement)
June 2017
Volume 23, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract NTOC-100: OVARIAN TUMOR-ASSOCIATED GRP78 INDUCES IMMUNOSUPPRESSION AND WITHAFERIN A (ASHWAGANDHA) ENHANCES ANTI-TUMOR IMMUNITY
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract NTOC-100: OVARIAN TUMOR-ASSOCIATED GRP78 INDUCES IMMUNOSUPPRESSION AND WITHAFERIN A (ASHWAGANDHA) ENHANCES ANTI-TUMOR IMMUNITY
Sa'Rah McNeal, Pincas Bitterman, Janice M Bahr, William P Hanafin, Sameer Sharma, Sanjib Basu and Animesh Barua
Clin Cancer Res June 1 2017 (23) (11 Supplement) NTOC-100; DOI: 10.1158/1557-3265.OVCASYMP16-NTOC-100

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract NTOC-100: OVARIAN TUMOR-ASSOCIATED GRP78 INDUCES IMMUNOSUPPRESSION AND WITHAFERIN A (ASHWAGANDHA) ENHANCES ANTI-TUMOR IMMUNITY
Sa'Rah McNeal, Pincas Bitterman, Janice M Bahr, William P Hanafin, Sameer Sharma, Sanjib Basu and Animesh Barua
Clin Cancer Res June 1 2017 (23) (11 Supplement) NTOC-100; DOI: 10.1158/1557-3265.OVCASYMP16-NTOC-100
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Novel Therapeutics for Ovarian Cancer

  • Abstract NTOC-115: ASSOCIATION BETWEEN NUCLEAR SYK PHOSPHORYLATION AND EGFR/ERBB2 PATHWAY AND POOR SURVIVAL IN HIGH GRADE SEROUS OVARIAN CANCER
  • Abstract NTOC-109: MULTI–FUNCTIONAL RNA NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTIC DRUGS FOR OVARIAN CANCER
  • Abstract NTOC-111: TARGETING COMPONENTS OF THE STAT3 SIGNALING PATHWAY FOR OVARIAN CANCER THERAPY: IMPLICATIONS FROM 3D CULTURE SYSTEMS
Show more Novel Therapeutics for Ovarian Cancer

Novel Therapeutics for Ovarian Cancer: Poster Presentations

  • Abstract NTOC-109: MULTI–FUNCTIONAL RNA NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTIC DRUGS FOR OVARIAN CANCER
  • Abstract NTOC-117: CD73 BLOCKADE OVERCOMES RESISTANCE TO AGONISTIC ANTI-CD137 ANTIBODY THERAPY IN OVARIAN CANCER
Show more Novel Therapeutics for Ovarian Cancer: Poster Presentations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement